News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Forte Biosciences, Inc. (NASDAQ: FBRX) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $4.00 price target on the stock.

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update

Anova to Manage Study of DB107 Following Newly Awarded $11.8M CIRM Grant [Yahoo! Finance]

Forte Biosciences, Inc. (NASDAQ: FBRX) was upgraded by analysts at LADENBURG THALM/SH SH from a "neutral" rating to a "buy" rating. They now have a $2.75 price target on the stock.

Form 10-Q Forte Biosciences, Inc. For: Mar 31

Form 8-K Forte Biosciences, Inc. For: May 13

Form 10-K/A Forte Biosciences, Inc. For: Dec 31

Form S-8 Forte Biosciences, Inc.

Form 4 Forte Biosciences, Inc. For: Apr 01 Filed by: Riley Antony A

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}